Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
World Journal of Urology
Erschienen in: World Journal of Urology 4/2006

01.09.2006 | Topic Paper

First-line treatment for symptomatic benign prostatic hyperplasia: is there a particular patient profile for a particular treatment?

verfasst von: Ricardo R. Gonzalez, Steven A. Kaplan

Erschienen in: World Journal of Urology | Ausgabe 4/2006

Einloggen, um Zugang zu erhalten

Abstract

When the range of treatment options for benign prostatic hyperplasia (BPH) is as broad as the BPH spectrum of symptoms, how should urologists and their patients choose the best initial treatment? Treatment goals should include reducing both lower urinary tract symptoms and relieving associated morbidities, such as urinary retention, persistent gross hematuria, recurrent infections, bladder stones, or renal insufficiency—which are all indications for surgery. However, if one views BPH as a chronic and progressive disease, should a primary goal of BPH management be the prevention of the BPH-associated morbidities? The goal of this paper is to provide a literature update regarding various treatment options in the setting of initial treatment for symptomatic BPH. Novel approaches to BPH management are discussed. In all cases, the risks and benefits of each treatment need to be considered and discussed with the patient; the decision is ultimately up to the patient and his urologist.
Literatur
1.
de la Rosette JJMCH, Alivizatos G, Madersbacher S, Peracchino M, Thomas D, Degrandchamps F, de Wildt M (2001) EAU guidelines on benign prostatic hyperplasia (BPH). Eur Urol 40:256–263CrossRefPubMed
2.
3.
Ball AJ, Feneley RCL, Abrahams PH (1981) The natural history of untreated ‘prostatism’. Br J Urol 53:613–616PubMedCrossRef
4.
Lepor H, Gup DI, Baumann M et al (1988) Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia. Urology 32(6):21–26CrossRefPubMed
5.
Narayan P, Tewari A (1998) Overview of alpha-blocker therapy for benign prostatic hyperplasia. Urology 51(4A):38–45CrossRefPubMed
6.
7.
Walsh PC, Madden JD, Harrod MJ et al (1974) Familial incomplete hermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med 291(18):944–949PubMedCrossRef
8.
McConnell JD, Bruskewitz R, Walsh P et al (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 338(9):557–563CrossRefPubMed
9.
Roehrborn CG, Boyle P, Bergner D et al (1999) Serum prostate-specific antigen and prostate volume predict long-term outcome in symptoms and flow rate: Results of a 4-year, randomized trial comparing finasteride vs. placebo. PLESS Study Group. Urology 54(4):662–669CrossRefPubMed
10.
Boyle P, Gould AL, Roehrborn CG (1996) Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 48:398–405PubMedCrossRef
11.
Roehrborn CG, McConnell J, Bonilla J et al (2000) For the proscar long-term efficacy and safety study: serum PSA concentration is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. J Urol 163:13–20CrossRefPubMed
12.
Roehrborn CG, McConnell J, Lieber M et al (1999) For the PLESS study group. Serum prostate-specific antigen is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. Urology 53:473–480CrossRefPubMed
13.
Roehrborn CG, Boyle P, Nickel JC et al (2002) Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60(3):434–441CrossRefPubMed
14.
Roehrborn CG, Boyle P, Bergner D et al (1999) Serum prostate-specific antigen and prostate volume predict long-term outcome in symptoms and flow rate: Results of a 4-year, randomized trial comparing finasteride vs. placebo. PLESS Study Group. Urology 54(4):662–669CrossRefPubMed
15.
Boyle P, Siami P, Wachs BH et al (2002) Effect of dutasteride on the risk of acute urinary retention and the need for surgical treatment [abstract 1479]. J Urol 167(suppl 4):372
16.
Donohue JF, Hayne D, Karnik U, Thomas DR, Foster MC (2005) Randomized, placebo-controlled trial showing that finasteride reduces prostatic vascularity rapidly within 2 weeks. BJU Int 96(9):1319–1322CrossRefPubMed
17.
Pareek G, Shevchuk M, Armenakas NA, Vasjovic L, Hochberg DA, Basillote JB, Fracchia JA (2003) The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients. J Urol 169(1):20–23CrossRefPubMed
18.
Peters TJ, Donovan JL, Kay HE, Abrams P, de la Rosette JJMCH, Porru D et al (1997) The international continence society benign prostatic hyperplasia study: the bothersomeness of urinary symptoms. J Urol 157:885CrossRefPubMed
19.
Hyman MJ, Groutz A, Blaivas JG (2001) Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol 166:550CrossRefPubMed
20.
Kaplan SA, Walmsley K, Te AE (2005) Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 174:2273–2276CrossRefPubMed
21.
Schiff JD, Mulhall JP (2004) The link between LUTS and ED: clinical and basic science evidence. J Androl 24(4):470–478
22.
Hopps CV, Mulhall JP (2003) Assessment of the impact of sildenafil citrate on lower urinary tract symptoms (LUTS) in men with erectile dysfunction (ED). Abstract #1401. J Urol 169(4):106
23.
McConnell JD, Roehrborn CG, Bautista AM et al (2003) For the MTOPS research group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. NEJM 285–296
24.
Lepor H, Williford WO, Barry MJ et al (1996) For the veterans affairs cooperative studies benign prostatic hyperplasia study group: the efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 335:533–539CrossRefPubMed
25.
Kaplan SA, McConnell JD, Roehrborn CG, Meehan AG, Lee MW, Noble WR, Kusek JW, Nyberg LM (2006) Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol 175:217–221CrossRefPubMed
26.
Larson TR (2002) Rationale and assessment of minimally invasive approaches to benign prostatic hyperplasia therapy. Urology 59(suppl 1):12–16CrossRefPubMed
27.
Larson TR, Bostwick DG, Corica A (1996) Temperature-correlated histopathologic changes following microwave thermoablation of obstructive tissue in patients with benign prostatic hyperplasia. Urology 47:463–69CrossRefPubMed
28.
Floratos DL, Kiemeney LA, Rossi L et al (2001) Long-term follow-up of randomized transurethral microwave thermotherapy versus transurethral prostatic resection study. J Urol 165:1533–1538CrossRefPubMed
29.
Bruskewitz R, Issa MM, Roehrborn CG et al (1998) A prospective, randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J Urol 159:1588–1593CrossRefPubMed
30.
Norby B, Nielsen HV, Frimodt-Moller PC (2002) Transurethral interstitial laser coagulation of the prostate and transurethral microwave thermotherapy vs transurethral resection or incision of the prostate: results of a randomized, controlled study in patients with symptomatic benign prostatic hyperplasia. BJU Int 90(9):853–862CrossRefPubMed
31.
Gonzalez RR, Te AE (2003) How do transurethral needle ablation of the prostate and transurethral microwave thermotherapy compare with transurethral prostatectomy? Curr Urol Rep 4:297–306PubMedCrossRef
32.
Roehrborn CG, Burkhard FC, Bruskewitz RC et al (1999) The effects of transurethral needle ablation and resection of the prostate on pressure flow urodynamics parameters: analysis of the Unites States randomized study. J Urol 162:92–97CrossRefPubMed
33.
Gupta N, Sivaramakrishna, Kumar R, Dogra PN, Seth A (2006) Comparison of standard transurethral resection, transurethral vapour resection and holmium laser enucleation of the prostate for managing benign prostatic hyperplasia of > 40g. BJU Int 97(1):85–89CrossRefPubMed
34.
Kuntz RM, Lehrich K (2002) Transurethral holmium laser enucleation versus transvesical open enucleation for prostate adenoma greater than 100 gm.: a randomized prospective trial of 120 patients. J Urol 168(4 Pt 1):1465–1469CrossRefPubMed
35.
Te A, Malloy TR, Stein BS, Ulchake JC, Nseyo UO, Mahmood AH, Malek RS (2004) Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia: 12-month results from the first United States multicenter prospective trial. J Urol 172:1404–1408CrossRefPubMed
36.
Sandhu JS, Ng C, VanderBrink BA, Egan E, Kaplan SA, Te AE (2004) High power potassium-titanyl-phosphate (KTP) photoselective laser vaporization of the prostate (PVP) for the treatment of benign prostatic hyperplasia (BPH) in men with large prostates. Urology 64:1155–1159CrossRefPubMed
37.
Sandhu JS, Nb CK, Gonzalez RR, Kaplan SA, Te AE (2005) Photoselective laser vaporization prostatectomy in men receiving anticoagulants. J Endourol 19(10):1196–1198CrossRefPubMed
Metadaten
Titel
First-line treatment for symptomatic benign prostatic hyperplasia: is there a particular patient profile for a particular treatment?
verfasst von
Ricardo R. Gonzalez
Steven A. Kaplan
Publikationsdatum
01.09.2006
Verlag
Springer-Verlag
Erschienen in
World Journal of Urology / Ausgabe 4/2006
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-006-0092-0

Weitere Artikel der Ausgabe 4/2006

World Journal of Urology 4/2006 Zur Ausgabe

Invited Editorial

BPH management at the turn of the twenty-first century: evolution or revolution

Topic Paper

What patients take without telling you: holistic approach for BPH

Original Article

Clinical decisions for treatment of different staged bladder cancer based on multitarget fluorescence in situ hybridization assays?

Topic Paper

Self-management in lower urinary tract symptoms: the next major therapeutic revolution

Topic Paper

How do I treat and follow my TUNA patients

Topic Paper

Management of non-complicated BPH: proposition of a renewed decision tree

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise